Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
DX1U3C
|
|||
Drug Name |
BI 456906
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Type 2 diabetes [ICD-11: 5A11; ICD-10: E08-E13] | Phase 2 | [1] | |
Company |
Boehringer Ingelheim; Zealand Pharma
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Agonist | [2] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT04153929) A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.. U.S. National Institutes of Health. | |||
REF 2 | Clinical pipeline report, company report or official report of Boehringer Ingelheim. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.